Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Dapagliflozin improves lipid profile and insulin resistance in T2DM patients
Última actualización 9 de septiembre de 2026
Key finding
BMI decreased by 2.1 kg/m² (p = 0.01)
This study investigated the effects of Dapagliflozin on lipid profiles and insulin resistance in patients with Type 2 Diabetes and heart failure, finding significant improvements in various metabolic markers.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of Dapagliflozin on lipid profiles and insulin resistance in patients with Type 2 Diabetes and heart failure, finding significant improvements in various metabolic markers.
Clinical relevance
These findings are clinically significant as they suggest that Dapagliflozin may not only aid in glycemic control but also improve cardiovascular health markers in patients with Type 2 Diabetes and heart failure, potentially reducing the risk of complications associated with these conditions.
Keep in mind
Limited sample size may affect generalizability Short duration of the study may not capture long-term effects Lack of diverse population representation
Published in
Referencia de la Revista
Publication details and source links for this paper.
Laxmi SB, Sarumathy S, Vengatesh M. Dapagliflozin Improves Lipid Profile and Insulin Resistance in Patients with Type 2 Diabetes and Heart Failure. Endocrine, Metabolic & Immune Disorders Drug Targets. 2026;26:E18715303398749. doi:10.2174/0118715303398749251027044323
Efectos Principales
Body Mass Index decreased by 2.1 kg/m² (p = 0.01)
Total Cholesterol decreased by 17.3 mg/dl (p = 0.02)
Fasting Plasma Glucose decreased by 88.5 mg/dl (p = 0.0001)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dapagliflozin 10 mg/day and BMI, Fasting Plasma Glucose (FPG), Fasting insulin levels, and 9 more.
This study contributes evidence to
Primary intervention
Dapagliflozin 10 mg/day
Primary outcomes
- BMI
- Fasting Plasma Glucose (FPG)
- Fasting insulin levels
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
12
Evidence pairs
12
Relationships
6
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
6
Related topics
12
Evidence pairs
2040
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 12 evidence relationships
- Includes primary outcome data
- Linked to 6 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Glycemic Control
matched_outcome
Evidencia relacionada
Tema de evidencia
Beta-Cell Function
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting insulin levels
Dapagliflozin 10 mg/day → Fasting insulin levels
Dapagliflozin 10 mg/day → Fasting insulin levels
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Dapagliflozin 10 mg/day → Fasting Plasma Glucose (FPG)
Dapagliflozin 10 mg/day → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerHomeostatic Model Assessment of Beta-cell function (HOMA-β)
Dapagliflozin 10 mg/day → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Dapagliflozin 10 mg/day → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerInsulin resistance
Dapagliflozin 10 mg/day → Insulin resistance
Dapagliflozin 10 mg/day → Insulin resistance
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerLow-density lipoprotein
Dapagliflozin 10 mg/day → Low-density lipoprotein
Dapagliflozin 10 mg/day → Low-density lipoprotein
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerPostprandial blood glucose
Dapagliflozin 10 mg/day → Postprandial blood glucose
Dapagliflozin 10 mg/day → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTotal cholesterol
Dapagliflozin 10 mg/day → Total cholesterol
Dapagliflozin 10 mg/day → Total cholesterol
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Dapagliflozin reduced triglycerides by 16.2 mg/dl (p = 0.01)
- HDL increased by 3.8 mg/dl (p = 0.001)
- HOMA-IR decreased by 1.05 (p = 0.002)
A quién se aplica
- Adults with Type 2 Diabetes
- Patients diagnosed with heart failure
Tener en Cuenta
- Results may not apply to non-diabetic populations
- Further studies needed to confirm long-term benefits
- Potential side effects of Dapagliflozin not addressed in this study
Entre Líneas
- Limited sample size may affect generalizability
- Short duration of the study may not capture long-term effects
- Lack of diverse population representation
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Dapagliflozin 10 mg/day and Fasting Glucose, Dapagliflozin 10 mg/day and Body Mass Index.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Dapagliflozin 10 mg/day → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
Dapagliflozin 10 mg/day → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Dapagliflozin 10 mg/day Evidence Hub
All studies on Dapagliflozin 10 mg/day
2 studies
intervention_hubContributes to Dapagliflozin 10 mg/day evidence base.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
2 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
1 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dapagliflozin 10 mg/day and Fasting Plasma Glucose (FPG)
Intervention: Dapagliflozin 10 mg/dayOutcome: Fasting Plasma Glucose (FPG)
2 results
All studies on Dapagliflozin 10 mg/day and BMI
Intervention: Dapagliflozin 10 mg/dayOutcome: BMI
1 results
All studies on Dapagliflozin 10 mg/day
Intervention: Dapagliflozin 10 mg/day
2 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
2 results
All studies measuring BMI
Outcome: BMI
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Dapagliflozin 10 mg/day improve fasting plasma glucose (FPG)?
Moderate Evidence
Dapagliflozin 10 mg/day appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Dapagliflozin 10 mg/day affect BMI?
Emerging Evidence
Dapagliflozin 10 mg/day appears to affect BMI.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Dapagliflozin 10 mg/day improve fasting insulin levels?
Emerging Evidence
Dapagliflozin 10 mg/day appears to improve fasting insulin levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting insulin levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Dapagliflozin 10 mg/day improve hdl cholesterol?
Emerging Evidence
Dapagliflozin 10 mg/day appears to improve hdl cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Structured exercise improves metabolic health in prediabetic adultsIntermittent Fasting Diet Improves Glycemic Control in Type 2 DiabetesVideo education improves dietary compliance for diabetesBariatric surgery improves glucose homeostasis in type 2 diabetes.Cyclic yoga improves metabolic health in women with diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.